drugset
Drugs / VRC-HIVADV014-00-VP
last change Nov 2017 re-read 2 minutes ago

VRC-HIVADV014-00-VP

also known as rAd5 · HIV rAd5 boost vaccine · HIV-1 recombinant Ad5 vaccine · Recombinant adenoviral serotype 5 (rAD5) vector vaccine

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · HIV Vaccine Trials Network · International AIDS Vaccine Initiative · Centers for Disease Control and Prevention · Merck Sharp & Dohme LLC · Objectif Recherche Vaccins SIDA
+5 more · Pfizer · Robert L. Murphy · US Military HIV Research Program · United States Department of Defense · Vaccine Research Center

Trials 22 · a red edge is where a trial was stopped

today NCT01386489 · Ph 1 NCT00955006 · Ph 1 NCT01054872 · Ph 1 NCT00976404 · Ph 2 NCT00865566 · Ph 2 NCT00709605 · Ph 1 NCT01549509 · Ph 1 NCT00384787 · Ph 1 NCT00119873 · Ph 1 NCT00123968 · Ph 1/2 NCT00091416 · Ph 1 NCT00321061 · Ph 1 NCT00270218 · Ph 1 NCT00270465 · Ph 1 NCT00124007 · Ph 1 NCT00125970 · Ph 2 NCT00109629 · Ph 1 NCT00108654 · Ph 1 NCT00102089 · Ph 1 NCT00083330 · Ph 1
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 116 trials
Phase 1 NCT01386489 Jun 2011 → Mar 2014 — National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00955006 May 2011 → Sep 2013 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01054872 Jan 2010 → Nov 2012 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00709605 Jun 2008 → May 2014 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01549509 Apr 2007 → Apr 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00384787 Nov 2006 → Nov 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00321061 Apr 2006 → Dec 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00270218 Feb 2006 → Aug 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00270465 Dec 2005 → Jun 2009 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00124007 Nov 2005 → Apr 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00123968 May 2006 → Jun 2012 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 25 trials
Phase 2 NCT00976404 Nov 2009 → Jul 2013 HIV infectious disease Robert L. Murphy Completed No outcome recorded
Phase 2 NCT00865566 May 2009 → Oct 2017 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Terminated No outcome recorded
Phase 2 NCT00125970 Sep 2005 → Feb 2008 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00498056 — HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 2 NCT00415649 — HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 23 sources stand behind the page.

FieldValueCited text
Known as VRC-HIVADV014-00-VP “receive antiretroviral therapy intensification alone or intensification plus injections of HIV DNA prime vaccine (4 mg VRC-HIVDNA016-00-VP) at weeks 8, 12, and 16, followed by...” PMID 26424549 ↗ Feb 2015
20

“This study will evaluate the safety and immunogenicity of an experimental multiclade HIV vaccine, VRC-HIVDNA016-00-VP, followed by a similarly structured adenovirus-vectored...” NCT00955006 ↗

“The vaccines used in this study are known as VRC-HIVDNA016-00-VP (called the "DNA vaccine") and VRC-HIVADV014-00-VP (called the "rAd5 vaccine").” NCT00321061 ↗

“The vaccines are VRC-HIVDNA016-00-VP (called the DNA vaccine) and VRC-HIVADV014-00-VP (called the rAd vaccine).” NCT00109629 ↗

NCT01386489 ↗

NCT00091416 ↗

NCT00102089 ↗

NCT00123968 ↗

NCT00108654 ↗

NCT00270218 ↗

NCT01549509 ↗

NCT00119873 ↗

NCT00125970 ↗

NCT00415649 ↗

NCT00270465 ↗

NCT00955006 ↗

NCT00498056 ↗

NCT00384787 ↗

NCT00709605 ↗

NCT00124007 ↗

NCT00083330 ↗
Known as HIV rAd5 boost vaccine “receive antiretroviral therapy intensification alone or intensification plus injections of HIV DNA prime vaccine (4 mg VRC-HIVDNA016-00-VP) at weeks 8, 12, and 16, followed by...” PMID 26424549 ↗ Feb 2015
Known as HIV-1 recombinant Ad5 vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01054872 ↗
Known as rAd5 “The vaccine, called VRC-HIVADV014-00-VP, or rAd5, is made using an adenovirus that has been modified to contain DNA that codes for three HIV proteins.” NCT00709605 ↗
2

“boosted IM at week 24 with VRC-HIVADV014-00-VP (rAd5) with N/S at 10(10) or 10(11) particle units (PU).” PMID 23577062 ↗ Apr 2013

“VRC-HIVADV014-00-VP (rAd5 vaccine) is composed of 4 recombinant nonreplicating adenoviral vectors” NCT01386489 ↗
Known as Recombinant adenoviral serotype 5 (rAD5) vector vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00865566 ↗
Modality Vaccine “adenoviral vector vaccine” NCT00091416 ↗
Route Intramuscular “Injections will be administered intramuscularly (IM).” NCT00083330 ↗